Disease-driven T cell activation predicts immune responses to vaccination against melanoma

Cancer Immun. 2003 Sep 9;3:12.

Abstract

Tumor vaccines may induce activation and expansion of specific CD8 T cells which can subsequently destroy tumor cells in cancer patients. This phenomenon can be observed in approximately 5-20% of vaccinated melanoma patients. We searched for factors associated with T cell responsiveness to peptide vaccines. Peptide antigen-specific T cells were quantified and characterized ex vivo before and after vaccination. T cell responses occurred primarily in patients with T cells that were already pre-activated before vaccination. Thus, peptide vaccines can efficiently boost CD8 T cells that are pre-activated by endogenous tumor antigen. Our results identify a new state of T cell responsiveness and help to explain and predict tumor vaccine efficacy.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / therapeutic use
  • Antibodies, Monoclonal / metabolism
  • Antibody Specificity
  • CD8-Positive T-Lymphocytes / immunology*
  • CD8-Positive T-Lymphocytes / virology
  • Cancer Vaccines / immunology*
  • Cancer Vaccines / therapeutic use
  • Epitopes / analysis
  • Epitopes / immunology
  • Epitopes / therapeutic use
  • Fluorescent Dyes / metabolism
  • Humans
  • Influenza A virus / immunology
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / metabolism
  • Lymphocyte Activation / immunology*
  • Melanoma / immunology*
  • Melanoma / therapy*
  • Neoplasm Proteins / analysis
  • Neoplasm Proteins / immunology
  • Neoplasm Proteins / therapeutic use
  • Peptide Fragments / analysis
  • Peptide Fragments / immunology
  • Peptide Fragments / therapeutic use
  • Predictive Value of Tests
  • Prognosis
  • T-Lymphocyte Subsets / immunology*
  • T-Lymphocyte Subsets / virology
  • Viral Matrix Proteins / analysis
  • Viral Matrix Proteins / immunology
  • Viral Matrix Proteins / therapeutic use

Substances

  • Adjuvants, Immunologic
  • Antibodies, Monoclonal
  • Cancer Vaccines
  • Epitopes
  • Fluorescent Dyes
  • MART-1-Melan-A(27-35) epitope
  • Neoplasm Proteins
  • Peptide Fragments
  • Viral Matrix Proteins
  • influenza virus membrane protein (58-66)